Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women

Giorgio Mustacchi, Alberto Scanni, Imma Capasso, Antonio Farris, Alfonso Pluchinotta, Giulio Isola

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: In the Phase III 'GRETA' trial 474 women aged ≥70 years with early breast cancer were randomly assigned to surgery plus tamoxifen for 5 years or tamoxifen alone for 5 years. This is a long-term update. Patients & methods: Focusing on patients still alive in 2003, outcome end points has been recalculated. Results: Median distant metastases disease-free survival is longer with tamoxifen alone for 5 years; (48.8 vs 37.9 months; p = 0.009). No difference was found in distant metastases rate, disease-free survival, breast cancer and overall survival. Conclusion: Primary endocrine treatment until the the best response, followed by minimal surgery and prosecution endocrine treatment for 5-10 years is a suitable option for elderly breast cancer patients. Delayed surgery does not prejudice overall survival.

Original languageEnglish
Pages (from-to)933-941
Number of pages9
JournalFuture Oncology
Volume11
Issue number6
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Tamoxifen
Breast Neoplasms
Disease-Free Survival
Neoplasm Metastasis
Survival
Therapeutics

Keywords

  • breast cancer
  • elderly
  • primary tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women. / Mustacchi, Giorgio; Scanni, Alberto; Capasso, Imma; Farris, Antonio; Pluchinotta, Alfonso; Isola, Giulio.

In: Future Oncology, Vol. 11, No. 6, 01.03.2015, p. 933-941.

Research output: Contribution to journalArticle

Mustacchi, Giorgio ; Scanni, Alberto ; Capasso, Imma ; Farris, Antonio ; Pluchinotta, Alfonso ; Isola, Giulio. / Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women. In: Future Oncology. 2015 ; Vol. 11, No. 6. pp. 933-941.
@article{8dd2ccb7540d4a75b43f97a0dd2291f3,
title = "Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women",
abstract = "Background: In the Phase III 'GRETA' trial 474 women aged ≥70 years with early breast cancer were randomly assigned to surgery plus tamoxifen for 5 years or tamoxifen alone for 5 years. This is a long-term update. Patients & methods: Focusing on patients still alive in 2003, outcome end points has been recalculated. Results: Median distant metastases disease-free survival is longer with tamoxifen alone for 5 years; (48.8 vs 37.9 months; p = 0.009). No difference was found in distant metastases rate, disease-free survival, breast cancer and overall survival. Conclusion: Primary endocrine treatment until the the best response, followed by minimal surgery and prosecution endocrine treatment for 5-10 years is a suitable option for elderly breast cancer patients. Delayed surgery does not prejudice overall survival.",
keywords = "breast cancer, elderly, primary tamoxifen",
author = "Giorgio Mustacchi and Alberto Scanni and Imma Capasso and Antonio Farris and Alfonso Pluchinotta and Giulio Isola",
year = "2015",
month = "3",
day = "1",
doi = "10.2217/fon.14.266",
language = "English",
volume = "11",
pages = "933--941",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women

AU - Mustacchi, Giorgio

AU - Scanni, Alberto

AU - Capasso, Imma

AU - Farris, Antonio

AU - Pluchinotta, Alfonso

AU - Isola, Giulio

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: In the Phase III 'GRETA' trial 474 women aged ≥70 years with early breast cancer were randomly assigned to surgery plus tamoxifen for 5 years or tamoxifen alone for 5 years. This is a long-term update. Patients & methods: Focusing on patients still alive in 2003, outcome end points has been recalculated. Results: Median distant metastases disease-free survival is longer with tamoxifen alone for 5 years; (48.8 vs 37.9 months; p = 0.009). No difference was found in distant metastases rate, disease-free survival, breast cancer and overall survival. Conclusion: Primary endocrine treatment until the the best response, followed by minimal surgery and prosecution endocrine treatment for 5-10 years is a suitable option for elderly breast cancer patients. Delayed surgery does not prejudice overall survival.

AB - Background: In the Phase III 'GRETA' trial 474 women aged ≥70 years with early breast cancer were randomly assigned to surgery plus tamoxifen for 5 years or tamoxifen alone for 5 years. This is a long-term update. Patients & methods: Focusing on patients still alive in 2003, outcome end points has been recalculated. Results: Median distant metastases disease-free survival is longer with tamoxifen alone for 5 years; (48.8 vs 37.9 months; p = 0.009). No difference was found in distant metastases rate, disease-free survival, breast cancer and overall survival. Conclusion: Primary endocrine treatment until the the best response, followed by minimal surgery and prosecution endocrine treatment for 5-10 years is a suitable option for elderly breast cancer patients. Delayed surgery does not prejudice overall survival.

KW - breast cancer

KW - elderly

KW - primary tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84924980674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924980674&partnerID=8YFLogxK

U2 - 10.2217/fon.14.266

DO - 10.2217/fon.14.266

M3 - Article

C2 - 25383659

AN - SCOPUS:84924980674

VL - 11

SP - 933

EP - 941

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 6

ER -